News | Breast Imaging | September 26, 2022

QTscan delivers safe, accurate monitoring of breast cancer treatment 

 

QTscan delivers safe, accurate monitoring of breast cancer treatment

September 26, 2022 — The U.S. Food and Drug Administration (FDA) has granted QT Imaging, Inc. 510(K) clearance to calculate the fibroglandular volume (FGV) of the breast and the ratio of FGV to total breast volume (TGV). This ratio can contribute to an assessment of risk for breast cancer and changes in this ratio can be used to measure the efficacy of medication used to treat or prevent breast cancer. 

Unlike traditional breast imaging modalities, the company's QTscan does not require radiation, injection, or compression, and is highly accurate (+ 0.2%), allowing earlier and more frequent monitoring for women undergoing non-surgical breast cancer treatments such as adjuvant chemotherapy, radiation therapy, cryotherapy, and hormone or selective hormone receptor modulation treatments. No other ultrasound-based breast imaging modality is cleared by the FDA to quantify fibroglandular volume. 

"The ability to determine a therapeutic clinical response using a quantitative volumetric method is crucial for effective and timely treatment of breast cancer and for patients at high risk for developing breast cancer who are receiving hormonal therapy. The FGV tool will allow this assessment to be made early and in follow-up to maximize treatment benefit, which is an exciting development for breast care patients," said Dr. Elaine Iuanow, a Breast Imaging specialist and medical consultant for QT Imaging. 

"We are excited to expand the tools available using low frequency transmitted ultrasound volography to serve women, especially those with dense breasts, providing an imaging option that is safe, comfortable, and effective," said Dr. John Klock, CEO, Chief Medical Officer and Founder of QT Imaging, Inc. 

The proposed indications for use, as designated by the FDA as breakthrough, are: 

"The QT Scanner 2000 Model A is for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast. The QT Scanner 2000 Model A software also calculates the breast fibroglandular tissue volume (FGV) value and the ratio of FGV to total breast volume (TBV) value as determined from reflection-mode and transmission-mode ultrasound images of a patient's breast. The device is not intended to be used as a replacement for screening mammography." FDA K220933 

For more information visit www.qtimaging.com 

Related Breast Density Content: 

Technologies to Watch in Breast Imaging 

Researchers Publish Exhaustive Review of Breast Density Assessment 

VIDEO: Women Benefit From Mammography Screening Beyond Age 75 

VIDEO: How Contrast-Enhanced Mammography Will Impact Breast Imaging 


Related Content

News | Breast Imaging

March 23, 2023 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 24, 2023
arrow
News | Nuclear Imaging

March 22, 2023 — A novel imaging modality that can visualize the distribution of medical radiopharmaceuticals with very ...

Time March 22, 2023
arrow
News | Breast Imaging

March 15, 2023 — In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer ...

Time March 15, 2023
arrow
News | Mammography

March 14, 2023 — Volpara Health Technologies, a global leader in software for the early detection of breast cancer ...

Time March 14, 2023
arrow
News | Coronavirus (COVID-19)

March 13, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR) ...

Time March 13, 2023
arrow
News | Artificial Intelligence

March 10, 2023 — Breast cancer undisputedly has the highest incidence rate in female patients. Moreover, out of the six ...

Time March 10, 2023
arrow
Feature | Breast Density

March 9, 2023 — Today, the U.S. Food and Drug Administration published updates to the mammography regulations to, among ...

Time March 09, 2023
arrow
News | Breast Density

March 9, 2023 — Research focused on the use of AI in breast screening was presented by Volpara Health Technologies Ltd ...

Time March 09, 2023
arrow
Feature | Women's Health | By Paola Wisner, Andy Smith, PhD, and Nikos Gkanatsios, PhD

Mammography has long been a vital tool in the radiologist toolkit for breast cancer imaging. It is an essential ...

Time March 09, 2023
arrow
News | Artificial Intelligence

March 2, 2023 — Qure.ai, a London-based medical Artificial Intelligence (AI) imaging company, has announced a new ...

Time March 02, 2023
arrow
Subscribe Now